Nakajima, Kenichi http://orcid.org/0000-0001-7188-8746
Nakata, Tomoaki
Doi, Takahiro
Verschure, Derk O.
Frantellizzi, Viviana
De Feo, Maria Silvia
Tada, Hayato
Verberne, Hein J.
Funding for this research was provided by:
JSPS Grants-in-Aid for Scientific Research (23K07203)
Article History
Received: 24 April 2024
Accepted: 12 July 2024
First Online: 21 July 2024
Declarations
:
: All methods were applied according to the ethical standards enshrined in the Declaration of Helsinki (2013 amendment) or comparable ethical standards. The Ethics Committee at Kanazawa University approved this retrospective study (2018 − 269 [3020]), and waived the need for patient consent to participate.
: Not applicable.
: K. Nakajima has a collaborative research agreement with PDRadiopharma (Tokyo, Japan), which markets <sup>123</sup>I-MIBG in Japan and belongs to a department endowed by PDRadiopharma, Nihon Medi-Physics (Tokyo, Japan), and Siemens Healthcare (Tokyo, Japan).